United StatesIncluding Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.
Already subscribed? Sign in →
No articles ingested yet for Deciduous Therapeutics. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Deciduous's lead program develops small-molecule, lipid-based agonists that activate invariant natural killer T (iNKT) cells, an innate immune population able to sense and destroy senescent cells. Rather than directly killing senescent cells with a cytotoxic drug, the approach restores the body's own immune surveillance so it clears the accumulating 'zombie' cells that drive age-related inflammation and disease. The founding research, published from the Bhushan lab, showed that activating iNKT cells removed senescent cells and improved metabolic outcomes in mouse models of diet-induced obesity. The program is preclinical.
Deciduous's discovery platform identifies molecules that harness endogenous immune mechanisms to eliminate senescent cells across age-related and fibrotic diseases. By focusing on immune activation rather than direct senolysis, the platform aims for durable, self-renewing clearance with a potentially wider therapeutic window than small-molecule senolytics. It generates the company's pipeline of immunotherapy candidates targeting conditions such as pulmonary fibrosis and metabolic disease, where senescent-cell burden contributes to tissue dysfunction.
